Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
MINDBIO THERAPEUTICS BEGINS DOSING MB22001 IN PHASE 2 CLINICAL TRIAL IN WORLD FIRST TAKE-HOME MICRODOSING STUDY IN PATIENTS WITH DEPRESSION World-first take-home approvals...
MINDBIO THERAPEUTICS BREAKTHROUGH DISCOVERY IN MICRODOSING CLINICAL TRIAL REVEALS SIGNIFICANT POSITIVE EFFECTS ON QUALITY OF SLEEPNew Discovery: MindBio's LSD-Microdosing Treatment Improves...
MINDBIO THERAPEUTICS CEO DEMONSTRATES HOW 1 MILLION MICRODOSES OF LSD CAN POTENTIALLY BE USED TO TREAT DEPRESSION 1 Million Microdoses used to create proprietary microdosing...
ETHICS APPROVAL FOR LANDMARK WORLD FIRST PHASE 2 CLINICAL TRIAL OF TAKE-HOME LSD-MICRODOSING FOR MAJOR DEPRESSIVE DISORDEREthics approval received for take-home LSD-Microdosing clinical...
PHASE 2 CLINICAL TRIAL HAS RECEIVED ETHICS APPROVAL FOR WORLD FIRST TAKE-HOME LSD-MICRODOSING TRIALS IN CANCER PATIENTS EXPERIENCING EMOTIONAL DISTRESSEthics approval granted The clinical trial...
MindBio Therapeutics Corp (CSE: MBIO) Reveals Scientific Paper in World-First Take-Home, LSD-Microdosing Clinical Trial in 80 Healthy Participants MindBio clinical trial...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.02 | 0.025 | 0.015 | 55033 | 0.02007555 | CS |
| 4 | 0 | 0 | 0.02 | 0.025 | 0.015 | 55041 | 0.02002846 | CS |
| 12 | -0.01 | -33.3333333333 | 0.03 | 0.035 | 0.015 | 93947 | 0.02421369 | CS |
| 26 | -0.02 | -50 | 0.04 | 0.05 | 0.015 | 60398 | 0.02692976 | CS |
| 52 | -0.005 | -20 | 0.025 | 0.085 | 0.015 | 57924 | 0.0381571 | CS |
| 156 | -0.54 | -96.4285714286 | 0.56 | 0.56 | 0.015 | 65127 | 0.05674096 | CS |
| 260 | -0.54 | -96.4285714286 | 0.56 | 0.56 | 0.015 | 65127 | 0.05674096 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
